Hispanic Heritage Month and Psychedelics
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
Participant Safety in Psychedelic Therapy
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
2026 First Quarter — Legislative Wrap Up
2026 is an important year for psychedelic state policy reform, reflecting the emerging evidence, creative leadership, and increasing confidence of a more mature movement. As the public deepens its understanding …
MAPS, in Partnership with the Shulgin Foundation, Launches Music Is the Bridge Video Series; First Episode Features Reggie Watts and Hamilton Morris
Lafayette, CA (March, XX, 2026) — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit advancing research, education, and advocacy around psychedelics and cannabis, …
MAPS Sends Expert Delegation to United Nations Commission on Narcotic Drugs
Vienna, Austria; March 9, 2026 —The Multidisciplinary Association for Psychedelic Studies (MAPS) will send senior academics, advocates, Veterans, and policy experts to the 69th session of the United …
In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reform
Washington, DC; February 4, 2026 — With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a robust resource …
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted …
MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. …
Green, Volat Transition from the MAPS Board of Directors to Committee Members
January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors. Mr. Green joined the MAPS board in December 2020 and — among other …
MAPS Submits 2025 Cannabis Data Safety Update Report to FDA for MJP2 Phase 2 Study
On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). The …
MAPS Supports Therapy Education for First-Ever Department of Defense-Affiliated MDMA-Assisted Therapy Pilot
December 23, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the completion of a therapy training initiative supporting clinicians participating in a Department of Defense …
Rescheduling Cannabis Doesn’t End Prohibition’s Harms…
The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification. Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment …